|
Synonyms: BMS-936558 | MDX-1106 | ONO-4538 | Opdivo®
nivolumab is an approved drug (FDA (2014), EMA (2015))
Compound class:
Antibody
Comment: Nivolumab is an IgG4 kappa immunoglobulin that is selective for PD-1, an immune-checkpoint receptor expressed on activated T-cells, monocytes, B-cells, natural killer (NK) T-cells, and dendritic cells [12]. This monoclonal is produced in Chinese hamster ovary cells by recombinant DNA technology. Nivolumab is an immuno-oncology drug.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Sequence analysis of the light and heavy chain variable region peptides of nivolumab shows exact matches with claimed peptide sequences of monoclonal 5C4 contained in patent WO2006121168 [10]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖
View more information in the IUPHAR Pharmacology Education Project: nivolumab |
| Immunopharmacology Comments |
| Nivolumab is an immuno-oncology drug, targeting various cancers via blockade of the PD-1 immune-checkpoint receptor expressed on activated T-cells, monocytes, B-cells, natural killer (NK) T-cells, and dendritic cells [12]. Checkpoint inhibition is a mechanism of action now widely accepted as efficacious for cancer immunotherapy [16,19]. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Lymphoma, Hodgkin, Classic; CHL |
Disease Ontology:
DOID:8567 OMIM: 236000 |
Approved drug for cHL. | |
| Renal cell carcinoma |
Disease Ontology:
DOID:4450 |
A combination therapy of nivolumab plus ipilimumab was granted FDA approval in April 2018 , for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma | 2,14 |
